丁苯酞苯环取代衍生物的合成及其抗凝活性研究

为了寻找潜在的治疗缺血性脑卒中候选化合物,以丁苯酞为起始原料,经硝化、还原、酰化、桑德迈尔反应合成了一系列丁苯酞苯环取代衍生物,其结构经¹H-NMR、¹³C-NMR和HRMS确证。体外抗血小板凝集活性测试结果表明:化合物3、6、8a、8c和9c对二磷酸腺苷(ADP)诱导的血小板凝集的抑制活性(IC₅₀=0.28～0.92 mmol·L^-1)优于先导化合物丁苯酞(IC₅₀=1.35 mmol·L^-1)和阳性对照阿司匹林(IC₅₀=1.15 mmol·L^-1);化合物3、6、8c和9c对花生四烯酸(AA)诱导的血小板凝集具有优良的抑制活性(IC₅₀=0.03～0.15mmol·L^-1),其中化合物6(IC₅₀=0.03 mmol·L^-1)优于阿司匹林(IC₅₀=0.04 mmol·L^-1...     

川芎嗪与丁苯酞及花椒毒醇拼合衍生物的合成及抗凝活性研究

为获得具有优异抗血小板凝集活性的新化合物,以丁苯酞、川芎嗪为起始原料,经硝化、还原、桑德迈尔反应、酯化和醚化反应合成了9个川芎嗪与丁苯酞、花椒毒酚拼合衍生物。目标化合物结构经¹H-NMR、¹³C-NMR和HRMS确证。并采用Born比浊法初步测试了化合物对二磷酸腺苷(ADP)和花生四烯酸(AA)所诱导的血小板凝集的抑制活性,结果显示化合物2f(IC₅₀=1.39 mmol·L^-1)、2g(IC₅₀=1.15 mmol·L^-1)、2h(IC₅₀=1.06 mmol·L^-1)和2i(IC₅₀=1.13 mmol·L^-1)对ADP诱导的血小板凝集具有一定的抑制活性,优于先导化合物川芎嗪(IC₅₀ =3.37 mmol·L^-1)和丁苯酞(IC₅₀ =1.67 mmol·L^-1)。化合物2f(...     

吡嗪类化合物的合成及其抗血小板凝集活性测试

为提高川芎嗪的抗血小板凝集活性,分别以不同的二胺、2,3-丁二酮和硫辛酸为起始原料,采用溴代、水解、环化、氧化、氢化、取代等反应,通过四条路线合成了7个川芎嗪衍生物,其结构经1H NMR、13C NMR及ESI-MS确证。采用Born比浊法初步测试了化合物的体外抗血小板凝集活性,结果显示,化合物1(IC50=0. 26mmol/L)、2(IC50=0. 27mmol/L)和7(IC50=0. 21mmol/L)对由二磷酸腺苷(ADP)诱导的血小板凝集具有一定的抑制活性,优于先导化合物川芎嗪(IC50=0. 49mmol/L)。因此,在不改变川芎嗪药效团的前提下对其进行不同程度的环化,能明显提高川芎嗪的抗血小板凝集活性,此研究为后期化合物的结构修饰提供了一定的参考价值。     

新型他克林-丁苯酞杂合物作为多靶点胆碱酯酶抑制剂的设计合成及活性评价（英文）

设计合成并评价了一系列他克林-丁苯酞杂合物作为多功能胆碱酯酶(ChE)抑制剂治疗阿尔茨海默病的活性.结果表明,他克林-丁苯酞杂合物对两种胆碱酯酶均表现出抑制活性.其中3-丁基-6-((7-((1,2,3,4-四氢吖啶-9-基)氨基)庚基)氧基)异苯并呋喃-1(3H)-酮(10b)显示出最优的乙酰胆碱酯酶(AChE,IC50=38.65nmol·L-1)抑制活性,高于他克林(IC50=200.70 nmol·L-1)约5倍. 3-丁基-6-((8-((6-氯-1,2,3,4-四氢吖啶-9-基)氨基)庚基)氧基)异苯并呋喃-1(3H)-酮(10g)显示出最好的丁酰胆碱酯酶(BuChE,IC50=33.69nmol·L-1)抑制活性,其值与他克林(IC50=27.12nmol·L-1)相似,高于多奈哌齐(IC50=7530nmol·L-1)约220倍.在大鼠海马体神经元细胞Aβ诱导损伤模型中,测试化合物对大鼠海马神经元细胞(Rat hippocampal neurons)中ROS水平的影响,结果显示,大多数化合物均能对Aβ1-42诱导的大鼠海马体神经元细胞分泌的ROS产生抑制作用.     

白藜芦醇衍生物的合成及抑制宫颈癌HeLa细胞肿瘤活性

以白藜芦醇、氯乙酰氯、对甲苯磺酰氯、对甲苯甲酰氯为原料,合成9种新的白藜芦醇衍生物,其结构经IR,1HNMR,13C NMR和HRMS所表征.用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法测试了目标化合物抑制宫颈癌HeLa细胞的肿瘤活性,结果表明:化合物4a,6a,7b,8b和11c对HeLa细胞的抑制活性比白藜芦醇高,其中化合物6a和8b的抑制效果最明显,其IC50值分别为22.7和18.0μmol/L,活性高于白藜芦醇(IC50=114μmol/L),且在150μmol/L浓度下对HeLa细胞的抑制率达95.5%和87.7%.     

具有四氢苯并[4,5]咪唑并[1,2-a]吡嗪骨架凝血酶抑制剂的设计合成及生物活性研究

以具有四氢苯并[4,5]咪唑并[1,2-a]吡嗪新骨架的凝血酶抑制剂1为先导化合物,设计合成了14个氨基甲酸酯衍生物(2a~6a,2b~6b和7~10).同时,在化合物1结构的基础上,引入具有抗血栓活性的川芎醇(HTMP),设计合成了新型结构的化合物11.目标化合物的结构均经1H NMR,13C NMR和HRMS确证.生物活性测试结果显示,所有目标化合物对凝血酶诱导的血小板聚集均有一定的抑制活性,其中化合物4b的抑制活性[IC50=(0.11±0.08)μmol/L]强于对照药达比加群酯[IC50=(0.60±0.05)μmol/L].在体内抗血栓活性测试中,化合物4b能以剂量依赖的方式减少大鼠静脉血栓的形成.化合物11对凝血酶诱导的血小板聚集的抑制活性较弱,但其抑制大鼠静脉血栓形成的作用与达比加群酯相当,这可能是由于化合物11在体内水解为川芎醇和化合物1,两者协同产生抗血栓作用所致.     

新型2,5-二取代-1,3,4-噻二唑衍生物的合成与生物活性

将自行合成的重要中间体2-氨基-5-取代-1,3,4-噻二唑(2)和2-氯硒基苯甲酰氯(6)反应,合成出了16个新颖的含苯并异硒唑酮结构的2,5-二取代-1,3,4-噻二唑衍生物7a~7p,利用IR,1H NMR和元素分析对目标产物进行了结构表征.评价了目标化合物的生物活性.实验结果表明,部分化合物具有抑制细胞分裂周期25 B磷酸酯酶(Cdc25B)的活性(IC50=1.67~6.66μmol·L-1).所有化合物对蛋白酪氨酸磷酸酯酶1B(PTP1B)均有抑制活性(IC50=0.73~4.50μmol·L-1),并且部分化合物的抑制活性高于阳性对照药物齐墩果酸(IC50=1.90μmol·L-1).化合物7k对人结肠癌(HCT-8)细胞具有体外抗肿瘤活性(IC50=12.54μmol·L-1).部分化合物对羟自由基(HO·)和超氧阴离子(O·-2)具有中等的清除能力,但对DPPH·均无清除能力.     

川芎嗪衍生物的设计、合成及抗血小板凝集活性研究

分别以川芎嗪(TMP)和邻苯二胺为起始原料,经KMn O4氧化、酯缩合、环化、还原等步骤合成了7个新型的川芎嗪衍生物,其结构经1H NMR、13C NMR及HRMS确证。并采用Born比浊法初步测试了化合物的体外抗血小板凝集活性。结果表明,化合物3和7对二磷酸腺苷(ADP)诱导的血小板凝集抑制率IC50分别为0.23mmol/L和0.27mmol/L,优于母体化合物川芎嗪(0.42mmol/L)。     

胡椒碱-双环酰胺衍生物的设计、合成及抗宫颈癌活性

以胡椒碱为母核进行结构改造,合成了一系列胡椒碱-双环酰胺衍生物;并用核磁共振氢谱(1H NMR),核磁共振碳谱(13C NMR)和高分辨质谱(HRMS)进行了结构确证.噻唑蓝(MTT)比色法测试结果表明,目标化合物对肾细胞(293T)、宫颈癌(HeLa)和乳腺癌(MDA-MB-321)细胞有良好的抑制活性,大多数衍生物对HeLa细胞的抑制活性优于阳性对照药5-氟尿嘧啶(5-FU)和胡椒碱.化合物6b对HeLa细胞的抗增殖活性最高,半数抑制浓度(IC50)为3.49μmol/L,对MDA-MB-321细胞的IC50值为20.89μmol/L.机理研究发现,化合物6b不仅可有效抑制HeLa细胞的迁移、侵袭、黏附和克隆能力,而且对HeLa细胞肿瘤异种移植物的生长表现出强烈的抑制作用.因此,化合物6b有可能成为肿瘤治疗中潜在的先导化合物.     

新颖3,4-二氢-苯并[b]氧杂棘-5(2H)-酮类化合物的合成以及蛋白酪氨酸激酶抑制活性研究

通过合成得到了一系列新颖的苯并[b]氧杂棘-5(2H)-酮类化合物单晶,结构经~1HNMR,~(13)CNMR和HREIMS确证,E-7-[(2,5-二羟基苯基)甲亚基]氨基-3,4-二氢-苯并[b]氧杂棘-5(2H)-酮(8k)和E-7-[(2,3,4-三羟基苯基)亚基]氨基-3,4-二氢-苯并[b]氧杂棘-5-(2H)-酮(8n)的结构经单晶X衍射方法进一步确证.系统测试了化合物对蛋白酪氨酸激酶(PTKs),如ErbB1,ErbB2,c-Met,ALK,FGFR1,RET和KDR等的抑制活性,结果表明含有邻苯二酚片段的化合物对蛋白酪氨酸激酶具有显著的抑制活性,其中E-7-[(3,4-二羟基苯基)甲亚基]氨基-3,4-二氢-苯并[b]氧杂棘-5(2H)-酮(8i)对ErbB1和ErbB2的IC50分别为1.0和0.33μmol/L,8n对RET的IC_(50)为0.7μmol/L,7-[(3,4-二羟基苯基)甲基]氨基-2,3,4,5-四氢-苯并[b]氧杂棘-5-醇(10b)对ErbB2的IC_(50)为1.02μmol/L.     

二氧化碳和丙烯直接合成甲基丙烯酸的NiPMo/TiO2催化剂的研究

用溶胶-凝胶法以磷钼酸(MPA)的镍盐溶液水解钛酸四丁酯制备了NiPMo/TiO2催化剂.使用ICP、 XRD、 TG-DTA、 IR、 TPD-MS和微反应技术研究了催化剂的化学组成、热稳定性、化学吸附性质和催化反应性能.杂多钼酸盐与TiO2通过O2-在TiO2表面发生了键合.在623 K下,杂多阴离子仍保持原有的Keggin结构.CO2在Lewis酸位Ni(Ⅱ)和Lewis碱位Ni-O-Mo的桥氧协同作用下生成CO2卧式吸附态Ni(Ⅱ)←O-(CO)←(O--Ni).丙烯有多种吸附态在催化剂上吸附.在563 K、 1 MPa和空速1500 h-1的反应条件下,丙烯的摩尔转化率为3.2%,产物MAA选择性为95%.     

Toward new camptothecins. Part 6: Synthesis of crucial ketones and their use in Friedländer reaction

In the context of the preparation of camptothecin and luotonin A analogs, the synthesis of some key keto-precursors and their use in Friedländer condensation are described. This paper also focuses on the stability of these keto intermediates and emphasizes the major differences between indolizinones and pyrroloquinazolinones series. Noteworthy is also the report of some original structures isolated as by-products of some experiments.     

CoFe2O4自形成磁性液体场致结构化对磁化的影响

The Langevin paramagnetic theory can’t describe the relation between magnetization of ferrofluids and applied magnetic field. The structuralization of ferrofluids, which is considered the main influence factor of the magnetization, is regarded. The part of magnetization works is deposited when the structure is forming. This action influences the magnetization of ferrofluids directly or indirectly. On the base of the “compressing” model, the Langevin function that usually describes the magnetization of ferrofluid is modified, and a well-fitted curve is obtained. An equation of the relation between the equivalent volume fraction after being “compressed” and the intensity of magnetic field is discovered, which approximately describes the process of magnetization. The relation between the approximate initial susceptibility and the volume fraction can be obtained from modified formula.     

Highly regioselective Buchwald–Hartwig amination at C-2 of 2,4-dichloropyridine enabling a novel approach to 2,4-bisanilinopyridine (BAPyd) libraries

The highly regioselective Buchwald–Hartwig amination at C-2 of the cheap and readily accessible reagent, 2,4-dichloropyridine with a range of anilines and heterocyclic amines is described. This new methodology is robust and provides a facile access to 4-chloro-N-phenylpyridin-2-amines on 0.25 mol scale. These intermediates undergo a further Buchwald–Hartwig amination at higher temperature to enable rapid exploration of the chemical space at C-4 and to provide a library of 2,4-bisaminopyridines.     

KMnO4-mediated oxidative CN bond cleavage of tertiary amines: Synthesis of amides and sulfonamides

KMnO₄-mediated oxidative CN bond cleavage of tertiary amines producing secondary amine was introduced, which was trapped by electrophiles (acyl chloride and sulfonyl chloride) to form amides and sulfonamides. The reaction could take place at mild condition, tolerating a wide range of function groups and affording products in moderate to excellent yields.     

Chemistry of heterocyclic compounds at the A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, over 50 years (Review)

The review contains a concise historical account and information on the most significant researches undertaken by the staff at the A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences on the Chemistry of Heterocyclic Compounds. Dedicated to Academician of the Russian Academy of Sciences B. A. Trofimov on his 70th jubilee. Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 10, pp. 1443–1502, October, 2008.     

Sulfur-directed metal-free and regiospecific methyl C(sp3)–H imidation of thioanisoles

Regiospecific and direct imidation of the methyl C(sp³)–H bond of thioanisoles is realized under mild and metal-free conditions with N-fluorobis(benzenesulfonyl)imide as an oxidant and nitrogen source. Proposed mechanism suggests that thionium ion intermediates and a Pummerer-type reaction are involved. The imidation has advantages such as high step-economy, excellent functionality tolerance, and regiospecificity, giving structurally diverse imidation products.     

Selective syntheses of 2H-1,3-oxazines and 1H-pyrrol-3(2H)-ones via temperature-dependent Rh(II)-carbenoid-mediated 2H-azirine-ring expansion

The Rh(II)-catalyzed reaction of 2-carbonyl-substituted 2H-azirines with ethyl 2-cyano-2-diazoacetate or 2-diazo-3,3,3-trifluoropropionate provides an easy access to 2H-1,3-oxazines and 1H-pyrrol-3(2H)-ones. These compounds can be selectively prepared from the same starting material using temperature as the only varied parameter. The 2-azabuta-1,3-diene intermediate, a common precursor for both heterocyclic products, isomerizes into 2H-1,3-oxazine under kinetic control, while 1H-pyrrol-3(2H)-one is the sole product of the reaction at elevated temperatures. According to DFT-calculations a one-atom oxazine ring contraction involving ring-opening to a 2-azabuta-1,3-diene intermediate, followed by a 1,5- and 1,2-prototropic shift leads to the consecutive formation of imidoylketene and azomethine ylide, which then further undergo cyclization to the pyrrole derivative.     

Synthesis of 1-benzyloxypyrazin-2(1H)-one derivatives

Different approaches for the synthesis of 1-benzyloxypyrazin-2(1H)-one derivatives from simple amino acids have been investigated. A library of 33 precursors for the preparation of N-hydroxy pyrazinones was obtained in moderate to good yields.